Germany's Altana is denying rumors that it is planning to delay the US launch of its respiratory drug Daxas. Its stock has been hit by talk of a delay. The drug, which has been tapped as a potential blockbuster, is currently in a Phase III US trial. European regulators are considering Altana's marketing application.
- read this story from AFX for more